The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

• Published in: Journal of thoracic oncology Vol. 5; no. 7; pp. 1060 - 1067
• Main Authors: Sebastian, Martin, Reck, Martin, Waller, Cornelius F., Kortsik, Cornelius, Frickhofen, Norbert, Schuler, Martin, Fritsch, Holger, Gaschler-Markefski, Birgit, Hanft, Gertraud, Munzert, Gerd, von Pawel, Joachim
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2010; International Association for the Study of Lung Cancer
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Adult; Aged; Aged, 80 and over; BI 2536; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Cell Cycle Proteins - antagonists & inhibitors; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Neoplasms, Squamous Cell - drug therapy; Neoplasms, Squamous Cell - pathology; Phase II; Plk-1 kinase inhibition; Polo-Like Kinase 1; Protein Serine-Threonine Kinases - antagonists & inhibitors; Proto-Oncogene Proteins - antagonists & inhibitors; Pteridines - therapeutic use; Salvage Therapy; Stage IIIB/IV NSCLC; Survival Rate; Treatment Failure; Treatment Outcome; BI 2536; Phase II; Stage IIIB/IV NSCLC; Plk-1 kinase inhibition
• ISSN: 1556-0864; 1556-1380
• DOI: 10.1097/JTO.0b013e3181d95dd4

To investigate the efficacy, safety, and pharmacokinetics of two dosing schedules of BI 2536, a novel polo-like kinase-1 inhibitor, in patients with relapsed stage IIIB/IV non-small cell lung cancer. Ninety-five patients were randomized to intravenous BI 2536 on day 1 (200 mg) or days 1 to 3 (50 or 60 mg) of a 21-day treatment course. BI 2536 doses were escalated beyond course 2 if well tolerated. The primary objective was response, and the secondary objectives were progression-free survival (PFS) and overall survival (OS), quality of life, safety, and pharmacokinetics. Primary statistical aim was to demonstrate the difference in objective response rate to historical placebo for both treatment groups. Four patients (4.2%) had a partial response; two were confirmed by independent review. Median PFS was 8.3 weeks (58 days 95% confidence interval [CI]: 48–85) and 7 weeks (49 days 95% CI: 46–70) assessed by investigator and independent review, respectively. Median OS was 28.7 weeks (201 days 95% CI: 180–305). No statistically significant difference was observed between the two treatment schedules regarding clinical benefit, PFS, or OS. Grade 4 neutropenia occurred in 37% of patients; common nonhematologic adverse events were fatigue (31%) and nausea (27%). Two deaths (pulmonary hemorrhage and sepsis) were considered drug related. There was a trend in favor of the days 1 to 3 dosing schedule in quality of life. BI 2536 displayed moderate interpatient variability. BI 2536 monotherapy has modest efficacy and favorable safety in relapsed non-small cell lung cancer. The findings support the further development of polo-like kinase-1 inhibitors within this indication.